dc.contributor
Institut Català de la Salut
dc.contributor
[Pasquali S] Molecular Pharmacology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy. [Vallacchi V, Lalli L] Translational Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy. [Collini P] Soft Tissue Tumor Pathology Unit, Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy. [Barisella M] Pathology Unit, ASST Fatebenefratelli Sacco, Milan, Italy. [Romagosa C] Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Pasquali, Sandro
dc.contributor.author
Vallacchi, Viviana
dc.contributor.author
Lalli, Luca
dc.contributor.author
Collini, Paola
dc.contributor.author
Barisella, Marta
dc.contributor.author
Romagosa, Cleofé
dc.date.accessioned
2025-10-24T10:37:07Z
dc.date.available
2025-10-24T10:37:07Z
dc.date.issued
2024-07-31T08:20:05Z
dc.date.issued
2024-07-31T08:20:05Z
dc.date.issued
2024-07-16
dc.identifier
Pasquali S, Vallacchi V, Lalli L, Collini P, Barisella M, Romagosa C, et al. Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapy. eBioMedicine. 2024 Jul 16;106:105220.
dc.identifier
https://hdl.handle.net/11351/11800
dc.identifier
10.1016/j.ebiom.2024.105220
dc.identifier.uri
https://hdl.handle.net/11351/11800
dc.description.abstract
Anthracycline; Neoadjuvant chemotherapy; Soft tissue sarcomas
dc.description.abstract
Antraciclina; Quimioterapia neoadyuvante; Sarcomas de tejidos blandos
dc.description.abstract
Antraciclina; Quimioteràpia neoadjuvant; Sarcomes de teixits tous
dc.description.abstract
Background: Anthracycline-based neoadjuvant chemotherapy (NAC) may modify tumour immune infiltrate. This study characterized immune infiltrate spatial distribution after NAC in primary high-risk soft tissue sarcomas (STS) and investigate association with prognosis.
Methods: The ISG-STS 1001 trial randomized STS patients to anthracycline plus ifosfamide (AI) or a histology-tailored (HT) NAC. Four areas of tumour specimens were sampled: the area showing the highest lymphocyte infiltrate (HI) at H&E; the area with lack of post-treatment changes (highest grade, HG); the area with post-treatment changes (lowest grade, LG); and the tumour edge (TE). CD3, CD8, PD-1, CD20, FOXP3, and CD163 were analyzed at immunohistochemistry and digital pathology. A machine learning method was used to generate sarcoma immune index scores (SIS) that predict patient disease-free and overall survival (DFS and OS).
Findings: Tumour infiltrating lymphocytes and PD-1+ cells together with CD163+ cells were more represented in STS histologies with complex compared to simple karyotype, while CD20+ B-cells were detected in both these histology groups. PD-1+ cells exerted a negative prognostic value irrespectively of their spatial distribution. Enrichment in CD20+ B-cells at HI and TE areas was associated with better patient outcomes. We generated a prognostic SIS for each tumour area, having the HI-SIS the best performance. Such prognostic value was driven by treatment with AI.
Interpretation: The different spatial distribution of immune populations and their different association with prognosis support NAC as a modifier of tumour immune infiltrate in STS.
dc.description.abstract
Pharmamar; Italian Ministry of Health [RF-2019-12370923; GR-2016-02362609]; 5 × 1000 Funds—2016, Italian Ministry of Health; AIRC Grant [ID#28546].
dc.format
application/pdf
dc.relation
eBioMedicine;106
dc.relation
https://doi.org/10.1016/j.ebiom.2024.105220
dc.rights
Attribution-NonCommercial 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Sarcoma - Tractament
dc.subject
Tumors de parts toves - Tractament
dc.subject
Avaluació de resultats (Assistència sanitària)
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Soft Tissue Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Combined Modality Therapy::Neoadjuvant Therapy
dc.subject
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Sarcoma
dc.subject
ANATOMY::Cells::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::Lymphocytes, Tumor-Infiltrating
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de los tejidos blandos
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamiento combinado::tratamiento neoadyuvante
dc.subject
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de tejido conjuntivo y de tejidos blandos::sarcoma
dc.subject
ANATOMÍA::células::células sanguíneas::leucocitos::leucocitos mononucleares::linfocitos::linfocitos infiltrantes de tumor
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
dc.title
Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapy
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
